TARA
Income statement / Annual
Last year (2024), Protara Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Protara Therapeutics, Inc.'s net income was -$44.60 M.
See Protara Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$341.00 K
|
$0.00
|
$0.00
|
$196.00 K
|
$16.00 K
|
$115.00 K
|
$148.00 K
|
$123.00 K
|
$57.00 K
|
| Gross Profit |
$0.00
|
-$341.00 K
|
$0.00
|
$0.00
|
-$196.00 K
|
-$16.00 K
|
-$115.00 K
|
-$148.00 K
|
-$123.00 K
|
-$57.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$31.70 M
|
$24.79 M
|
$16.81 M
|
$21.09 M
|
$11.88 M
|
$6.44 M
|
$15.51 M
|
$21.69 M
|
$18.87 M
|
$12.38 M
|
| General & Administrative Expenses |
$17.45 M
|
$18.62 M
|
$20.74 M
|
$26.40 M
|
$0.00
|
$8.82 M
|
$10.57 M
|
$105.99 K
|
$9.84 M
|
$8.49 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.42 M
|
-$123.00 K
|
-$57.00 K
|
| Selling, General & Administrative Expenses |
$17.45 M
|
$18.62 M
|
$20.74 M
|
$26.40 M
|
$22.37 M
|
$8.82 M
|
$10.57 M
|
$8.53 M
|
$9.71 M
|
$8.43 M
|
| Other Expenses |
$0.00
|
-$137.00 K
|
$29.52 M
|
$0.00
|
$0.00
|
$0.00
|
$207.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$49.15 M
|
$43.27 M
|
$67.06 M
|
$47.49 M
|
$34.25 M
|
$15.25 M
|
$26.08 M
|
$30.21 M
|
$28.58 M
|
$20.81 M
|
| Cost And Expenses |
$49.15 M
|
$43.61 M
|
$67.06 M
|
$47.49 M
|
$34.44 M
|
$15.25 M
|
$26.08 M
|
$30.36 M
|
$28.71 M
|
$20.87 M
|
| Interest Income |
$4.14 M
|
$2.73 M
|
$1.11 M
|
$237.00 K
|
$466.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$1.14 M
|
$1.74 M
|
$34.00 K
|
$0.00
|
$0.00
|
$259.00 K
|
$193.00 K
|
$144.00 K
|
| Depreciation & Amortization |
$332.00 K
|
$341.00 K
|
$248.00 K
|
$117.00 K
|
$196.00 K
|
$16.00 K
|
$115.00 K
|
$148.00 K
|
$123.00 K
|
$57.00 K
|
| EBITDA |
-$48.82 M |
-$43.27 M |
-$64.57 M |
-$45.40 M |
-$33.78 M |
-$7.81 M |
-$20.61 M |
-$29.82 M |
-$28.40 M |
-$21.32 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.56 M
|
$3.19 M
|
$1.11 M
|
$237.00 K
|
$466.00 K
|
$0.00
|
$643.00 K
|
$398.00 K
|
$179.00 K
|
-$507.00 K
|
| Income Before Tax |
-$44.60 M
|
-$40.42 M
|
-$65.95 M
|
-$47.25 M
|
-$33.98 M
|
-$14.99 M
|
-$25.44 M
|
-$29.96 M
|
-$28.53 M
|
-$21.38 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$262.00 K
|
$5.35 M
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$44.60 M
|
-$40.42 M
|
-$65.95 M
|
-$47.25 M
|
-$33.98 M
|
-$14.99 M
|
-$25.44 M
|
-$29.96 M
|
-$28.53 M
|
-$21.38 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.17 |
-3.57 |
-5.86 |
-4.2 |
-4.7 |
-3.63 |
-9.93 |
-69.38 |
-68.9 |
-51.94 |
| EPS Diluted |
-2.17 |
-3.57 |
-5.86 |
-4.2 |
-4.7 |
-3.63 |
-9.93 |
-69.38 |
-68.9 |
-51.94 |
| Weighted Average Shares Out |
$20.59 M
|
$11.33 M
|
$11.26 M
|
$11.23 M
|
$7.23 M
|
$4.06 M
|
$2.56 M
|
$431.86 K
|
$414.04 K
|
$411.60 K
|
| Weighted Average Shares Out Diluted |
$20.59 M
|
$11.33 M
|
$11.26 M
|
$11.23 M
|
$7.23 M
|
$4.06 M
|
$2.56 M
|
$431.86 K
|
$414.04 K
|
$411.60 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
